literature

HIV mutation literature information.

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.

PMID: 31330378 2020 Journal of global antimicrobial resistance

Abstract: Before INSTI treatment one patient harboured the major INSTI-RM R263K and three patients the accessory INSTI-RMs T97A.

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.

PMID: 32675772 2020 Journal of acquired immune deficiency syndromes (1999)

Abstract: Participants with screening HIV-1 RNA <50 copies/mL for >=6 months; no prior virologic failure; and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1:1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 (early-switch group) or to continue their current antiretroviral regimen and, if virologically suppressed at week 48, switch to dolutegravir plus rilpivirine at week 52 (late-switch group) until week 148.

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.

PMID: 30648124 2019 Open forum infectious diseases

Conclusion: R263K was confirmed by next-generation sequencing (NGS) using an analysis percentage minority variant threshold of >20%.

Conclusion: Follow-up NGS sequencing 3 months after the first resistance test showed the R263K mutation at <5% in a sample with a VL of 61 000 copies/mL.

Conclusion: Poor engagement continued for 18 months; at this later, time integrase resistance testing showed the R263K mutation conferring low-level resistance to DTG and raltegravir, with intermediate resistance to elvitegravir.

Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.

PMID: 30753573 2019 The Journal of antimicrobial chemotherapy

Abstract: INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.

PMID: 31037930 2019 Revista espanola de quimioterapia

Discussion: Of note, in our survey, R263K signature mutation that affects the efficacy of DTG was not observed.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

PMID: 31430369 2019 The Journal of antimicrobial chemotherapy

Method: Primary INSTI resistance (-R) substitutions were T66I/A/K, E92Q/G, T97A, F121Y, Y143R/H/C, S147G, Q148H/K/R, N155H/S and R263K in IN.

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.

PMID: 31169022 2019 AIDS research and human retroviruses

Abstract: Prevalence of elvitegravir-associated DRMs T66A/I/K, E92Q, S147G, and the dolutegravir-associated DRM R263K increased.

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.

PMID: 31551948 2019 Frontiers in microbiology

Result: This residue is involved in resistance to DTG when bearing the M50I mutation in combination with R263K and is selected in vitro by DTG treatment.

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

PMID: 29239896 2018 AIDS (London, England)

Method: Additionally, if the M50I/R263K mutation was present, we termed it as intermediate resistance to BIC.

Discussion: A selection of R263K/M50I has been described in virus outgrowth assay for BIC that resulted 2.8-fold reduction of BIC-susceptibility, but M50I alone did not have any effect.

Discussion: In breakthrough selections, M50I emerges after R263K and provides replication advantage to R263K containing virus.

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.

PMID: 29346270 2018 Viruses

Introduction: A few additional VF occurred in the SAILING trial after W48 and R263K mutation was detected in one of them.

Introduction: First In Vitro Data on R263K Mutant.

Introduction: First In Vivo Data on R263K Mutation Selection.